Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ME Therapeutics HoldingMETXF 14 Market Cap is $41.25 Mil as of Aug. 26, 2026. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,421 Biotechnology companies, ME Therapeutics Holding ranks worse than 67.21% on this metric.
ME Therapeutics Holding's quarterly market cap
increased
from Nov. 2025 ($88.57 Mil) to Feb. 2026 ($88.64 Mil) but then
stayed the same
from Feb. 2026 ($88.64 Mil) to May. 2026 ($88.64 Mil).
ME Therapeutics Holding's annual market cap
increased
from Aug. 2023 ($0.00 Mil) to Aug. 2024 ($74.24 Mil) and
increased
from Aug. 2024 ($74.24 Mil) to Aug. 2025 ($87.21 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ME Therapeutics Holding's Enterprise Value for Today is $41.02 Mil.
ME Therapeutics Holding (OTCPK:METXF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ME Therapeutics Holding Market Cap Related Terms
ME Therapeutics Holding Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ME Therapeutics Holding's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ME Therapeutics Holding Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Market Cap distribution charts can be found below:
* The bar in red indicates where ME Therapeutics Holding's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ME Therapeutics Holding's Market Cap for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ME Therapeutics Holding (METXF) has a Market Cap of $41.25 Mil as of Aug. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ME Therapeutics Holding and its competitors. According to the industry distribution chart, ME Therapeutics Holding ranks #955 out of 1421 companies in the Biotechnology industry, placing it in the top 67.2%.
Is ME Therapeutics Holding's Market Cap too high?
ME Therapeutics Holding's current Market Cap is $41.25 Mil. The Biotechnology industry median Market Cap is 123.85. ME Therapeutics Holding's value of $41.25 Mil is 66.7% below this industry median. Based on the distribution chart, ME Therapeutics Holding ranks #955 out of 1421 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #955 out of 1421 companies for Market Cap. This places ME Therapeutics Holding in the lower half of its industry. The industry median Market Cap is 123.85. ME Therapeutics Holding's value of $41.25 Mil is 66.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 123.85, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ME Therapeutics Holding's current Market Cap of $41.25 Mil is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ME Therapeutics Holding and its competitors. For the Biotechnology industry, the median Market Cap is 123.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ME Therapeutics Holding's current Market Cap is $41.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current Market Cap of $41.25 Mil. The current Market Cap is $41.25 Mil and 66.7% below the Biotechnology industry median of 123.85. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current Market Cap is $41.25 Mil as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score
Get the complete analysis for METXF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
METXF has been successfully added to your 
